精品国产一区二区桃色

Journal News

JBC: In reading histone modifications, an oncoprotein is modified in return

Sasha Mushegian
Sept. 1, 2018

Turning genes on and off is an intricate process involving communication among many different types of proteins that interact with DNA. These communications can go awry, resulting in conditions such as cancer.

The lightbulb symbolizes TRIM24, a “histone reader” protein, which binds chromatin. Chromatin association triggers signaling to TRIM24, marked or “illuminated” by a post-translational modification called SUMOylation.Courtesy of Srikanth Appikonda

Researchers at the have uncovered an unusual form of crosstalk between proteins that affect gene expression, suggesting new ways of inhibiting metastasis in cancer. were published in the Journal of Biological Chemistry.

Tripartite motif-containing 24, or TRIM24, is an oncoprotein, meaning it is found in higher abundance in many types of cancer cells than in healthy cells. at MD Anderson studies this protein. Previous research has shown that TRIM24 is, among other things, an epigenetic reader. This means that it detects certain chemical modifications of histones — proteins around which DNA is coiled — and induces other proteins to change their behavior in response, resulting in a different pattern of genes being turned on than if the histone had not been modified.

In the new study, , a former postdoctoral fellow in Barton’s lab, found something unusual. Not only did TRIM24 “read” histone modifications, but the act of reading resulted in TRIM24 itself being modified with a small protein tag called a small ubiquitinlike modifier, or SUMO. In other words, reading the message of the histone made the reader carry its own chemical message.

“This is the first time that we know of that the (histone) itself is imposing a code on the modifiers or readers,” Barton said.

What does the addition of SUMO to TRIM24 accomplish? Appikonda, graduate student Kaushik Thakkar and the other team members performed experiments to see how the genes that TRIM24 turned on and off in cancer cells differed when TRIM24 didn’t have SUMO attached.

They found that the SUMO-modified TRIM24 seemed to be regulating genes involved in adhesion between cells. Cell adhesion determines whether cancer cells stay in one spot or can travel and metastasize through the body.

“That’s really where these cell-adhesion molecules are coming into play: metastasis and migration of cancer cells,” Barton said.

Multiple proteins are involved in adhesion, and TRIM24 turned some off and some on. Therefore, it’s not yet clear what net effect TRIM24 has on metastasis in cancer patients. But understanding that TRIM24 is involved in this process gives researchers a place to look to learn how to stop it.

In the meantime, the SUMO modification also can be used as a possible marker in studies of other types of potential new drugs. Cancer researchers often are interested in disrupting TRIM24’s interaction with histones in order to prevent aberrant gene expression. By tracking whether TRIM24 has SUMO attached, researchers can test whether a potential drug has blocked the interaction successfully.

“The exciting thing about learning more about modifications of TRIM24, such as SUMO, is to be able to develop antibodies or other means to detect its presence,” Barton said. “(This) may be a better predictor of cancers in early stages or could be linked to potential for metastasis.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Sasha Mushegian

Sasha Mushegian is a postdoctoral fellow at Georgetown University. Follow her on Twitter.

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
News

Cracking cancer鈥檚 code through functional connections

July 2, 2025

A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.